Goldman Sachs Group Inc. Decreases Stock Position in Pulse Biosciences, Inc $PLSE

Goldman Sachs Group Inc. cut its position in Pulse Biosciences, Inc (NASDAQ:PLSE) by 22.3% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 39,047 shares of the company’s stock after selling 11,208 shares during the quarter. Goldman Sachs Group Inc. owned 0.06% of Pulse Biosciences worth $628,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the stock. Rhumbline Advisers boosted its stake in Pulse Biosciences by 6.3% during the 1st quarter. Rhumbline Advisers now owns 27,375 shares of the company’s stock valued at $440,000 after acquiring an additional 1,614 shares during the last quarter. Strs Ohio bought a new position in Pulse Biosciences during the 1st quarter valued at $286,000. Jane Street Group LLC bought a new position in Pulse Biosciences during the 1st quarter valued at $323,000. Panoramic Capital LLC boosted its stake in Pulse Biosciences by 8.5% during the 1st quarter. Panoramic Capital LLC now owns 52,723 shares of the company’s stock valued at $848,000 after acquiring an additional 4,152 shares during the last quarter. Finally, AlphaQuest LLC boosted its stake in Pulse Biosciences by 68.0% during the 1st quarter. AlphaQuest LLC now owns 3,116 shares of the company’s stock valued at $50,000 after acquiring an additional 1,261 shares during the last quarter. 76.95% of the stock is currently owned by institutional investors.

Pulse Biosciences Stock Performance

Shares of NASDAQ:PLSE opened at $17.67 on Thursday. The stock has a market capitalization of $1.19 billion, a price-to-earnings ratio of -16.83 and a beta of 1.68. Pulse Biosciences, Inc has a 1-year low of $13.77 and a 1-year high of $25.00. The company’s fifty day moving average is $15.69 and its two-hundred day moving average is $16.16.

Pulse Biosciences (NASDAQ:PLSE) last issued its earnings results on Tuesday, August 12th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02).

Insiders Place Their Bets

In other Pulse Biosciences news, insider Kevin Patrick Danahy sold 20,000 shares of the stock in a transaction on Thursday, September 18th. The shares were sold at an average price of $18.49, for a total transaction of $369,800.00. Following the sale, the insider directly owned 43,298 shares of the company’s stock, valued at approximately $800,580.02. This represents a 31.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Robert W. Duggan acquired 34,659 shares of the company’s stock in a transaction that occurred on Wednesday, September 10th. The stock was purchased at an average cost of $14.66 per share, for a total transaction of $508,100.94. Following the acquisition, the director owned 47,551,200 shares in the company, valued at approximately $697,100,592. This trade represents a 0.07% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 90,400 shares of company stock valued at $1,465,142. Company insiders own 74.60% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Oppenheimer began coverage on shares of Pulse Biosciences in a research note on Monday, July 7th. They set an “outperform” rating and a $22.00 price objective on the stock. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $22.00.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.